The program combines Mindbloom's ketamine therapy protocol with preparation, integration, and in-session content from Shari Botwin , a leading trauma therapist, author, and survivor of PTSDAUSTIN, Texas, June 18, 2024 /PRNewswire/ -- Mindbloom , the largest provider of psychedelic medicine, today announced the launch of a first-of-its-kind ketamine therapy program designed for people recovering from PTSD.PTSD is a leading cause of disability in the United States, affecting 13 million people every year – but FDA has not approved any new PTSD treatments in 25 years.Mindbloom"Seventeen veterans die from suicide every day because last-generation treatments like antidepressants and psychotherapy aren't working" said Mindbloom CEO and Founder Dylan Beynon. "Congress and the VA are taking steps to support psychedelic medicine, but with FDA approval of MDMA therapy in question, Mindbloom is ensuring that trauma survivors don't have to wait for treatment that could save their lives."Mindbloom's new program includes ketamine therapy protocols that have shown incredible effectiveness for depression and anxiety , and combines them with content from trauma expert Shari Botwin:Six ketamine therapy sessions focusing on unique issues, including Conquering Guilt, Rising Above Shame, Learning to Trust Yourself, Learning to Trust Others, Healing Through Grieving, and Reclaiming What Was Lostfocusing on unique issues, including Conquering Guilt, Rising Above Shame, Learning to Trust Yourself, Learning to Trust Others, Healing Through Grieving, and Reclaiming What Was Lost Audio, video, and written content by Shari Botwin for preparation, treatment, and integrationfor preparation, treatment, and integration One-on-one coaching from Mindbloom guides, and access to group integration circles"This program is designed for people who have experienced traumatic events of various kinds and, just like me, are hoping to live full, safe and happy lives, Botwin says. "While no one walks away from trauma feeling the exact same thing, my hope is to share insights, tools, and practices that cover the broad spectrum of unmanageable and horrific life experiences to help survivors heal."Mindbloom's new program adds to a library of expert-led programs for unique mental health challenges:About Mindbloom:Mindbloom is the largest provider of psychedelic medicine, offering ketamine therapy programs that combine evidence-based medicine with coaching, content, and community. Mindbloom's psychiatric clinicians facilitate over 275,000 at-home ketamine therapy sessions each year in 36 states, and Mindbloom's remarkable treatment outcomes were published in the largest peer-reviewed study of ketamine therapy. For more information, visit www.mindbloom.com .About Shari Botwin:Shari Botwin, LCSW, has counseled survivors in recovery from all types of traumas in her Cherry Hill, New Jersey private practice for over twenty-eight years. She has written three books, and her latest – Stolen Childhoods: Thriving After Abuse – focuses on reclaiming life in adulthood for survivors of childhood abuse

At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world dataAUSTIN, Texas, June 14, 2024 /PRNewswire/ -- Mindbloom , the leading provider of psychedelic therapy, announced today the findings of the largest peer-reviewed study in the history of ketamine therapy and psychedelic medicine. The study was published in the Journal of Affective Disorders, and was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom.Key Findings:Largest study : The study reviewed data from 11,441 Mindbloom clients, making it the most comprehensive examination of ketamine therapy to date: The study reviewed data from 11,441 Mindbloom clients, making it the most comprehensive examination of ketamine therapy to date Effectiveness : 62% of clients reported clinically-significant improvements in depression or anxiety, with 28% achieving remission: 62% of clients reported clinically-significant improvements in depression or anxiety, with 28% achieving remission Rapid results : Significant symptom improvements were found after only four sessions: Significant symptom improvements were found after only four sessions Safety : Fewer than 5% of clients reported adverse effects: Fewer than 5% of clients reported adverse effects Benefits of continued treatment : 84% of clients who experienced significant improvements in an initial round of treatment maintained improvements or recovered in a second round"Millions of Americans are suffering from mental illness, and haven't been helped by traditional treatments," said co-author and Mindbloom Medical Director Dr. Leonardo Vando. "This study confirms that at-home ketamine therapy can be an effective and fast-acting treatment for depression and anxiety, and shows why psychedelic therapy is going to be a first-line treatment in the next few years."The authors noted that the extensive support offered through Mindbloom – including 1:1 coaching, therapeutic content, and group integration – drives the effectiveness and safety of the treatment. In addition, Mindbloom's at-home ketamine therapy programs overcome barriers like cost, provider availability, and stigma that prevent people from accessing effective mental health care."Mindbloom's programs are successful because of our at-home model, not in spite of it," said Mindbloom's Founder and CEO Dylan Beynon. "Telehealth makes treatment more accessible and affordable, allowing clients to heal from the comfort of home

Austin-based ketamine therapy provider Mindbloom is launching its Mastermind Series, the first-of-its-kind, expert-led psychedelic therapy program for overcoming severe mental and emotional health challenges.